Clinical Trials Details

GOG-3110; A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Treatment of Physician’s Choice in Participants with B7-H4-Positive Advanced/Metastatic Endometrial Cancer Who Progressed After Platinum and Anti-PD-1/Anti-PD-L1 Therapy

Summary

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.

More information